CD8 Inhibitors
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that affects T cell activation and proliferation. By suppressing mTOR signaling, rapamycin can indirectly reduce the effectiveness and number of CD8+ cytotoxic T cells, impacting their immune response capabilities. | ||||||
Aspirin | 50-78-2 | sc-202471 sc-202471A | 5 g 50 g | $20.00 $42.00 | 4 | |
Inhibits cyclooxygenase enzymes, reducing prostaglandin production. Lower prostaglandin levels can modulate T cell responses, indirectly impacting CD8+ T cell activity and reducing inflammation-mediated activation. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Affects multiple signaling pathways including NF-κB, down-regulating pro-inflammatory cytokines and potentially modulating T-cell mediated immune responses, thus indirectly affecting CD8+ T cell function. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
A tyrosine kinase inhibitor that impacts vascular endothelial growth factor pathways, which can alter the tumor microenvironment and potentially decrease the recruitment and effectiveness of CD8+ T cells in cancer immunosurveillance. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Targets multiple kinases involved in tumor growth and angiogenesis. It may indirectly impair CD8+ T cell function by altering the cytokine environment and reducing their tumor infiltration and cytotoxic activity. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
Known primarily for its effects on metabolic pathways, metformin can also modulate immune responses. It has been shown to affect AMPK activation, which indirectly could impact CD8+ T cell activation and function in metabolic-sensitive pathways. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Modulates the immune system and cytokine production, potentially impacting the inflammatory environment and indirectly reducing CD8+ T cell activation and their effectiveness in immune responses. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $57.00 | 1 | |
It affects endosomal pH and can interfere with antigen processing, potentially reducing the activation and efficacy of CD8+ T cells. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Primarily used as a BCR-ABL tyrosine kinase inhibitor, imatinib also affects other kinases and could modulate the immune environment, indirectly affecting CD8+ T cell activity especially in leukemic contexts. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Similar to imatinib, nilotinib targets tyrosine kinases and can alter the cytokine profiles and immune environment, potentially impacting CD8+ T cell functionality and their role in immunosurveillance. | ||||||